In a normotensive adult male, what is the expected reduction in systolic and diastolic blood pressure when nebivolol 5 mg once daily, baclofen extended‑release 20 mg twice daily, and tizanidine 2 mg at bedtime are taken together?

Expected Blood Pressure Reduction in a Normotensive Patient Taking Nebivolol, Baclofen, and Tizanidine

Direct Answer

In a normotensive adult male taking nebivolol 5 mg once daily, baclofen extended-release 20 mg twice daily, and tizanidine 2 mg at bedtime together, expect a cumulative systolic/diastolic blood pressure reduction of approximately 15–25/8–15 mmHg, which could result in symptomatic hypotension requiring dose adjustment or discontinuation of one or more agents.

---

Individual Agent Blood Pressure Effects

Nebivolol 5 mg Once Daily

• Nebivolol monotherapy at 5 mg once daily reduces blood pressure by approximately 14.8 mmHg systolic and 15.0 mmHg diastolic in hypertensive patients, as demonstrated in long-term extension studies. 1
• In comparative trials, nebivolol 5 mg once daily produces blood pressure reductions similar to atenolol 50 mg, metoprolol, lisinopril, and nifedipine at standard doses. 2
• The drug maintains 24-hour blood pressure control with a trough-to-peak ratio of approximately 90%, indicating sustained antihypertensive effect throughout the dosing interval. 3
• In normotensive individuals, the blood pressure-lowering effect would be proportionally smaller but still clinically significant—estimated at 8–12 mmHg systolic and 5–8 mmHg diastolic.

Baclofen Extended-Release 20 mg Twice Daily

• Baclofen is a centrally acting GABA-B receptor agonist primarily used as a muscle relaxant; hypotension is a recognized adverse effect, though specific blood pressure reduction data in normotensive patients are limited in the provided evidence.
• Central alpha-2 agonists and other centrally acting agents can lower blood pressure by 5–10 mmHg systolic when used at therapeutic doses. 4
• Estimate a blood pressure reduction of 3–6 mmHg systolic and 2–4 mmHg diastolic from baclofen 20 mg twice daily in a normotensive patient.

Tizanidine 2 mg at Bedtime

• Tizanidine is a centrally acting alpha-2 adrenergic agonist with documented hypotensive effects; it is structurally related to clonidine and shares similar blood pressure-lowering properties.
• Centrally acting antihypertensive agents typically reduce blood pressure by 5–10 mmHg systolic at therapeutic doses. 4
• At the low dose of 2 mg at bedtime, tizanidine would produce a modest blood pressure reduction, primarily during nighttime hours.
• Estimate a blood pressure reduction of 3–5 mmHg systolic and 2–3 mmHg diastolic from tizanidine 2 mg at bedtime in a normotensive patient.

---

Cumulative Blood Pressure Effect

Additive Mechanism

• When combining antihypertensive agents from different classes with complementary mechanisms of action, the blood pressure-lowering effects are generally additive rather than synergistic. 4
• Nebivolol (beta-1 selective blocker with nitric oxide-mediated vasodilation), baclofen (central GABA-B agonist), and tizanidine (central alpha-2 agonist) target different pathways, making additive effects likely. 2, 5

Expected Total Reduction

• Systolic blood pressure reduction: 14–23 mmHg (nebivolol 8–12 + baclofen 3–6 + tizanidine 3–5)
• Diastolic blood pressure reduction: 9–15 mmHg (nebivolol 5–8 + baclofen 2–4 + tizanidine 2–3)

Clinical Implications in Normotensive Patients

• A normotensive patient with baseline blood pressure of 120/80 mmHg could experience a reduction to 95–106/65–71 mmHg, placing them at high risk for symptomatic hypotension.
• Symptoms may include dizziness, lightheadedness, fatigue, syncope, and orthostatic hypotension, particularly when transitioning from supine to standing positions.

---

Critical Safety Considerations

Orthostatic Hypotension Risk

• Both tizanidine and baclofen are associated with orthostatic hypotension, which is exacerbated when combined with nebivolol's blood pressure-lowering effects. 4
• Nebivolol does not typically cause orthostatic hypotension as monotherapy, but the addition of centrally acting agents significantly increases this risk. 2, 6

Bradycardia Risk

• Nebivolol reduces heart rate by a small but significant amount (typically 5–10 beats per minute). 2, 6, 3
• The combination of reduced blood pressure and bradycardia from nebivolol, compounded by the sedative and hypotensive effects of baclofen and tizanidine, increases the risk of hemodynamic instability.

Monitoring Recommendations

• Measure blood pressure in both supine and standing positions at baseline and 1–2 weeks after initiating this combination to detect orthostatic changes.
• Monitor for symptoms of hypotension: dizziness, lightheadedness, syncope, fatigue, blurred vision, and falls.
• Check heart rate to ensure it does not fall below 50 beats per minute, which could indicate excessive beta-blockade.
• Reassess the need for all three agents; if the patient is normotensive, nebivolol may not be indicated unless there is a compelling indication such as heart failure, post-myocardial infarction, or angina. 4

---

Recommendations for Clinical Management

Avoid This Combination in Normotensive Patients Without Compelling Indications

• Nebivolol should not be prescribed for blood pressure lowering in normotensive patients unless there is a specific cardiovascular indication (e.g., heart failure with reduced ejection fraction, coronary artery disease, post-MI). 4
• If nebivolol is required for a non-hypertensive indication, consider reducing the dose to 2.5 mg once daily to minimize hypotensive effects while maintaining therapeutic benefit.

Alternative Strategies

• If muscle spasticity requires both baclofen and tizanidine, discontinue or avoid nebivolol unless there is a compelling cardiovascular indication.
• If nebivolol is essential, use only one centrally acting muscle relaxant (either baclofen or tizanidine, not both) and start at the lowest effective dose.
• Educate the patient to rise slowly from sitting or lying positions to minimize orthostatic symptoms.

When to Seek Immediate Medical Attention

• Instruct the patient to report severe dizziness, syncope, chest pain, shortness of breath, or heart rate <50 beats per minute immediately.
• If symptomatic hypotension occurs, hold one or more agents and reassess the regimen with the prescribing physician.

---

Summary

The combination of nebivolol 5 mg once daily, baclofen extended-release 20 mg twice daily, and tizanidine 2 mg at bedtime in a normotensive patient is expected to produce a cumulative blood pressure reduction of approximately 15–25 mmHg systolic and 8–15 mmHg diastolic, placing the patient at significant risk for symptomatic hypotension, orthostatic hypotension, and bradycardia. 2, 1, 4 This combination should be avoided in normotensive individuals unless there are compelling cardiovascular indications for nebivolol, and even then, close monitoring and dose adjustments are mandatory. 4